| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 0450 |
Emergency room services |
6,457 |
5,624 |
$252.54 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
896 |
847 |
$153.81 |
| 70450 |
Computed tomography, head or brain; without contrast material |
127 |
124 |
$116.55 |
| 80053 |
Comprehensive metabolic panel |
3,260 |
2,927 |
$22.26 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,666 |
3,209 |
$16.20 |
| 81025 |
|
232 |
221 |
$5.60 |
| 83690 |
|
653 |
597 |
$4.86 |
| 36415 |
Collection of venous blood by venipuncture |
1,559 |
1,370 |
$3.57 |
| 81002 |
|
435 |
403 |
$1.72 |
| 0270 |
|
1,288 |
888 |
$0.02 |
| J3490 |
Unclassified drugs |
1,860 |
987 |
$0.01 |
| 0250 |
|
1,574 |
1,382 |
$0.00 |
| 71045 |
Radiologic examination, chest; single view |
1,519 |
1,442 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
49 |
41 |
$0.00 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
699 |
622 |
$0.00 |
| 84703 |
|
514 |
472 |
$0.00 |
| 0636 |
|
503 |
448 |
$0.00 |
| 84484 |
|
1,065 |
843 |
$0.00 |
| 0301 |
|
75 |
70 |
$0.00 |
| 0710 |
|
564 |
512 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
341 |
307 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
259 |
257 |
$0.00 |
| 81001 |
|
941 |
878 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
37 |
37 |
$0.00 |
| 0271 |
|
364 |
341 |
$0.00 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
312 |
284 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
126 |
122 |
$0.00 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
339 |
308 |
$0.00 |
| 0259 |
|
225 |
159 |
$0.00 |
| 0305 |
|
75 |
71 |
$0.00 |
| 83605 |
|
258 |
217 |
$0.00 |
| S9445 |
Patient education, not otherwise classified, non-physician provider, individual, per session |
211 |
138 |
$0.00 |
| 86141 |
|
27 |
27 |
$0.00 |
| 0370 |
|
124 |
114 |
$0.00 |
| 0352 |
|
12 |
12 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
30 |
30 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
86 |
77 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
60 |
54 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
41 |
40 |
$0.00 |
| 99000 |
|
165 |
161 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
15 |
12 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
12 |
12 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
15 |
12 |
$0.00 |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
39 |
39 |
$0.00 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
15 |
14 |
$0.00 |
| 85730 |
|
43 |
37 |
$0.00 |
| 86140 |
|
33 |
32 |
$0.00 |
| 0307 |
|
14 |
14 |
$0.00 |
| 86901 |
|
14 |
12 |
$0.00 |
| 81003 |
|
1,084 |
1,009 |
$0.00 |
| 0320 |
|
244 |
228 |
$0.00 |
| 0121 |
|
159 |
152 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
258 |
256 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,680 |
1,536 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
368 |
340 |
$0.00 |
| 0272 |
|
575 |
533 |
$0.00 |
| 0300 |
|
620 |
557 |
$0.00 |
| 85610 |
|
1,179 |
1,102 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
922 |
810 |
$0.00 |
| 0360 |
|
95 |
91 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
602 |
544 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
29 |
29 |
$0.00 |
| 84145 |
|
14 |
13 |
$0.00 |
| 80306 |
|
58 |
52 |
$0.00 |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
175 |
172 |
$0.00 |
| 0730 |
|
71 |
67 |
$0.00 |
| 0402 |
|
26 |
26 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
56 |
44 |
$0.00 |
| 86900 |
|
14 |
12 |
$0.00 |
| 0460 |
|
60 |
54 |
$0.00 |
| 0278 |
|
14 |
14 |
$0.00 |
| 0160 |
|
31 |
24 |
$0.00 |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
40 |
36 |
$0.00 |